Source news

globenewswire News

20 stories
globenewswire

Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses

Data Demonstrate Vamorolone’s Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical DosesCORAL GABLES, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") NASDAQ:CPRX, a comme…

GlobeNewswire en
StocksUS
globenewswire

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic

TARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) NASDAQ:ALLR, a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the United States Paten…

GlobeNewswire en
StocksUS
globenewswire

Alm. Brand A/S – Weekly report on share buybacks

Transactions during 23 June 2026 – 29 June 2026On 7 May 2026, Alm. Brand A/S announced a share buy-back program of up to DKK 593 million, as described in company announcement no. 23/2026.The program is carried out in accordance with the Regulation No 596/2014 of the European Parliament and Council…

GlobeNewswire en
StocksDK
globenewswire

American Lithium Minerals, Inc. (OTC: AMLM) Acquires 100% Interest in High Grade New Zealand Gold–Antimony Projects

CARSON CITY, Nevada, June 30, 2026 (GLOBE NEWSWIRE) -- American Lithium Minerals, Inc. OTC:AMLM (“AMLM” or the “Company”), an exploration-stage mining company focused on gold, silver, lithium, rare earth elements, and other critical metals, is pleased to announce that it has completed the acquisiti…

GlobeNewswire en
StocksNZ
globenewswire

Atlantic International Relaunches As Circle8, Reflecting Its Evolution Into A Global Technology and Workforce Solutions Platform

Company to Trade on Nasdaq Under Ticker CIRCGuus Franke Appointed Chief Executive Officer While Continuing as Executive ChairmanENGLEWOOD CLIFFS, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- Atlantic International Corp. NASDAQ:ATLN today announced a new chapter in the Company's evolution. Effective imme…

GlobeNewswire en
StocksUS
globenewswire

Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants

June 30, 2026Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and WarrantsBiodexa Pharmaceuticals PLC, NASDAQ:BDRX (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative p…

GlobeNewswire en
corp_bondStocksUS
globenewswire

Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)

Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated safety profile for AdvSM patientsAPEX NDA is third submission for bezuclastinib in six months; PEAK a…

GlobeNewswire en
ETFsStocksUS
globenewswire

Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1

GeneTAC® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. NASDAQ:DSGN, a clinical-stage biotechnology company developing treatments for serious d…

GlobeNewswire en
ETFsStocksUS
globenewswire

Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer

- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial -- Data demonstrate Olvi-Vec–mediated modulation of the tumor microenvironment and immune activation -- Translational analyses ident…

GlobeNewswire en
ETFsStocksUS
globenewswire

Max Power Confirms Basin-Scale Natural Hydrogen Potential in Saskatchewan with Bracken Well, 325 Km from Lawson Discovery

Independent GLJ Ltd. review identifies multiple prospective Natural Hydrogen and helium zones at Bracken, part of the 750 sq. km permitted Grasslands Project never previously drilled for Natural Hydrogen or helium.A soon-to-be-launched completions and testing program at Bracken will target new disc…

GlobeNewswire en
StocksCA